Our partnership with Jointown Pharmaceutical Group (SSE 600998) opens a fast track for devices made on our platform — into a network serving over 100,000 pharmacies and more than 10,000 county-level and above public hospitals. Validation, registration, manufacturing and market access on one chain.
Jointown Pharmaceutical Group Co., Ltd. (Shanghai Stock Exchange, ticker 600998) is one of China's largest pharmaceutical and medical device distributors, with 2025 revenue above RMB 161.3 billion. Through our partnership, devices manufactured on our platform and holding a registration certificate can enter that network directly — without hunting for provincial distributors or building a sales organisation from nothing.
Figures above are Jointown's publicly disclosed operating data, from its 2025 annual report. Brands already distributed include Johnson & Johnson, Abbott, Fresenius and LivaNova.
Your product has to be compliant and clinically worthwhile, and the distributor will run its own commercial assessment — that much is obvious, and we are not going to pretend otherwise. But a new product knocking on the door alone, and the same product introduced by a long-standing manufacturing partner with the full compliance file attached, are two very different routes. What the partnership secures is the second one: your product gets a serious look, not a silent queue.
No cold approach. The product and its compliance file go directly to the relevant category team, assembled by us.
Made by a licensed contract manufacturer whose system cleared registration inspection with zero findings — quality and supply reliability, the distributor's two main worries, are already half answered.
Capacity scheduling, pack formats and delivery cadence can be planned against real channel demand, instead of brokered between two unrelated suppliers.
In-hospital, out-of-hospital, online and primary care open together — no province-by-province distributor hunt.
We put the product into the right category assessment and assemble the product, compliance and supply-capability documentation the distributor needs.
Established provincial distribution and warehousing reaching public hospitals and retail outlets nationwide.
In-hospital supply chain programmes already running at a number of hospitals provide an existing route inside the institution.
Out-of-hospital accounts for over 70% of their sales — retail-profile products can open online and OTC routes in parallel.
Price, rebates, territory and exclusivity are agreed directly between you and the distributor; we do not set your pricing. Channel access is also not a condition of working with us — contract manufacturing alone is entirely normal, and many registrants have their own sales organisation.
Technology out of clinical practice rarely arrives with a sales organisation. Channel access is what turns translation into revenue.
Put limited capital into the product and its registration, and enter an existing network for distribution — far more realistic, and far faster, than a national field team.
After the domestic certificate is granted, local distribution is the part an overseas company can least easily solve alone — and where this route is worth the most.